OncLive TV

Dr Al Hallak on the Associated Risks of Cirrhosis and Portal Hypertension in HCC

January 24th 2025

Mohammed Najeeb Al Hallak, MD, MS, discusses treatment considerations for patients with HCC and the associated risks of cirrhosis and portal hypertension.

Dr Montero on Unmet Treatment Needs for HER2+ Metastatic Breast Cancer

January 23rd 2025

Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.

Dr Jurczak on the Role of Nemtabrutinib in R/R Follicular Lymphoma Management

January 23rd 2025

Wojciech Jurczak, MD, discusses the role of nemtabrutinib in the management of relapsed or refractory follicular lymphoma.

Dr Singer on Choosing Between Frontline IO/IO and IO/TKI Regimens in RCC

January 23rd 2025

Adam E. Singer, MD, PhD, discusses factors that inform the choice between IO/IO and IO/TKI regimens for patients with renal cell carcinoma.

Dr Burke on the Assessment of Barriers to Initiating Venetoclax-Based Regimens for CLL

January 23rd 2025

John M. Burke, MD, discusses the barriers to initiating venetoclax-based regimens for chronic lymphocytic leukemia.

Dr McGregor on Future Biomarker Analyses With Nivolumab Plus Ipilimumab in Bladder Cancer

January 23rd 2025

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

Dr Zackon on Next Steps for Evaluating the Real-World Use of Bispecific Antibodies in R/R Myeloma

January 23rd 2025

Ira Zackon, MD, discusses the real-world use of bispecific antibodies for patients with R/R multiple myeloma in the community oncology setting.

Dr Berchuck on Next Steps for Evaluating a Novel Liquid Biopsy for PSMA in mCRPC

January 23rd 2025

Jacob E. Berchuck, MD, shares next steps in research for a novel epigenomic liquid biopsy test for detecting PSMA in castration-resistant prostate cancer.

Dr Braun on Future Directions for Research Into Protein Glycosylation in RCC

January 22nd 2025

David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma

January 22nd 2025

Dr Hayek on the Rationale of Assessing Laparoscopic Surgery in Advanced Ovarian Cancer

January 22nd 2025

Judy Hayek, MD, explains the rationale of a retrospective analysis evaluating laparoscopic vs open surgery in advanced ovarian cancer.

Dr Ghia on Potential Future Roles for Ibrutinib Plus Venetoclax in CLL

January 22nd 2025

Paolo Ghia, MD, PhD, discusses future research directions and potential roles for first-line, fixed-duration ibrutinib plus venetoclax in CLL.

Odzer on ERBB2 Copy Number Ratio as a Predictive Biomarker in HER2+ Breast Cancer

January 22nd 2025

Nicole Odzer discusses the utility of ERBB2 copy number ratio as a predictive biomarker in HER2+ breast cancer.

Dr Rifkin on the Role of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma

January 21st 2025

Robert M. Rifkin, MD, FACP, offers advice to colleagues about belantamab mafodotin as a treatment option for patients with relapsed/refractory multiple myeloma.

Dr Brentjens on Efforts to Expand CAR T-Cell Therapy Beyond B-Cell Malignancies

January 21st 2025

Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell therapy and ongoing efforts to expand its application beyond B-cell malignancies.

Dr Zhang on the Efficacy of SIM0270 Plus Everolimus in ER+/HER2− Advanced Breast Cancer

January 21st 2025

Jian Zhang, MD, discusses SIM0270, a brain-penetrant oral SERD, in combination with everolimus, in ER-positive, HER2-negative advanced breast cancer.

Dr Niemann on the Investigation of Ibrutinib Plus Ventoclax in CLL

January 21st 2025

Carsten Niemann, MD, PhD, discusses long-term follow-up data from the phase 3 GLOW trial evaluating fixed-duration ibrutinib plus venetoclax in CLL.

Dr Park on the FDA Approval of Obe-Cel in Adult R/R ALL

January 21st 2025

Jae Park, MD, discusses the FDA approval of obe-cel for adult patients with relapsed or refractory acute lymphoblastic leukemia.

Dr Braun on Protein Glycosylation as a Potential Biomarker of Response in RCC

January 20th 2025

David A. Braun, MD, PhD, discusses the potential use of protein glycosylation as a biomarker of response in renal cell carcinoma.

Dr McGregor on the Potential Use of Checkpoint Inhibitors in Rare GU Cancers

January 20th 2025

Bradley McGregor, MD, discusses the rationale for investigating nivolumab plus ipilimumab in advanced, rare genitourinary malignancies.